IDXX · 8-K · 20260804PR090033

Revenue Performance and Mix

IDEXX LABORATORIES INC /DE · 2026-08-04 · Importance 47 · Surprise 22 · No source text

Second-quarter revenue was $1,216.6 million, up 9.7% reported and 9.0% organically from $1,109.5 million in the prior-year quarter. CAG revenue increased 9.4% to $1,118.2 million, Water revenue increased 14.8% to $58.6 million, and LPD revenue increased 10.8% to $35.2 million. CAG Diagnostics recurring revenue rose 11.0% to $974.7 million, led by IDEXX VetLab consumables growth of 14.7% to $430.3 million and reference laboratory diagnostic and consulting services growth of 10.6% to $406.7 million. CAG capital instrument revenue declined 19.5% to $47.2 million as the company lapped the prior-year broad availability of IDEXX inVue Dx, while veterinary software, services and diagnostic imaging systems revenue grew 12.2% to $96.3 million.

Key facts

• Projected CAG Diagnostics recurring revenue reported growth for 2026: 10.1% - 11.3%; projected organic growth: 9.5% - 10.7%. source
• Second quarter 2026 revenues: $1,217 million for the second quarter of 2026, an increase of 10% as reported and 9% organic. source
• CAG Diagnostics recurring revenue growth for Q2 2026: 11% as reported and 10% organic. source
• Revenue by segment for Q2 2026: CAG $1,118,236; Water $58,564; LPD $35,181; Other $4,604; Total $1,216,585. source
• IDEXX VetLab consumables generated 15% reported and 14% organic revenue growth in the quarter. source
• Reference laboratory diagnostic and consulting services generated 11% reported and 10% organic revenue growth in the quarter. source
• Veterinary software, services and diagnostic imaging systems revenues grew 12% on a reported and organic basis for the quarter. source
• Water revenue growth for Q2 2026: 15% as reported and 13% organic. source

Impact estimates